Accolade, Inc.

ACCD

US00437E1029

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 10:57:29 30/04/2024 pm IST			5-day change	1st Jan Change
7.855 ^USD	-4.09%		-15.94%	-34.55%

05:06pm	Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating	MT
26/04	Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating	MT

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 3000E Value Index

June 25, 2021 at 09:30 am IST

Latest news about Accolade, Inc.

Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating	08:36pm	MT
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating	26/04	MT
Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024	26/04
Accolade, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 29, 2024	26/04	CI
Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating	22/04	MT
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President	19/03	CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	13/03
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target	26/02	MT
Accolade Insider Sold Shares Worth $1,554,504, According to a Recent SEC Filing	12/01	MT
Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	11/01
Accolade Shares Surge After Raymond James Upgrade, Fiscal Q3 Results	10/01	MT
Raymond James Adjusts Accolade's Price Target to $16 From $12, Keeps Outperform Rating	09/01	MT
Accolade Fiscal Q3 Loss Halves, Sales Jump; Issues Guidance	09/01	MT
Transcript : Accolade, Inc., Q3 2024 Earnings Call, Jan 08, 2024	09/01
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ending February 29, 2024 and Year Ending February 28, 2025	09/01	CI
Accolade Guides For Q4 Revenue of $121.5-$125.5 Million, vs CIQ Analyst Consensus of $126.4 Million	09/01	MT
Accolade, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	09/01	CI
North American Morning Briefing : Boeing Drags Down Dow Futures	08/01	DJ
Stifel Cuts Accolade's Price Target to $15 From $17, Keeps Buy Rating	04/01	MT
Piper Sandler Adjusts Accolade's Price Target to $12 From $15, Maintains Overweight Rating	22/11	MT
Accolade to Repurchase $76.5 Million of Outstanding Debt	17/11	MT
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey	10/23/10	RE
Canaccord Genuity Adjusts Accolade Price Target to $17 From $18, Maintains Buy Rating	05/23/05	MT
Truist Securities Adjusts Price Target on Accolade to $15 From $17, Keeps Buy Rating	05/23/05	MT
Raymond James Adjusts Price Target on Accolade to $12 From $15, Keeps Outperform Rating	05/23/05	MT

Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, womenâs health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

Sector

Healthcare Facilities & Services

Calendar

27/06/2024 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Accolade, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.19 USD

Average target price

13.33 USD

Spread / Average Target

+62.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
ACCOLADE, INC.	-34.55%	642M
CVS HEALTH CORPORATION	-14.37%	85.02B
HCA HEALTHCARE, INC.	+14.38%	82.37B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.29B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.11%	17.21B
FRESENIUS SE & CO. KGAA	-0.36%	16.7B
QUEST DIAGNOSTICS INCORPORATED	+1.02%	15.5B
FRESENIUS MEDICAL CARE AG	+4.32%	12.15B
EUROFINS SCIENTIFIC SE	-2.34%	12.13B
DAVITA INC.	+31.88%	12.12B

Other Healthcare Facilities & Services

Accolade, Inc.

Equities

ACCD

US00437E1029

Healthcare Facilities & Services

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 3000E Value Index

Latest news about Accolade, Inc.

Chart Accolade, Inc.

Company Profile

Income Statement Evolution

Ratings for Accolade, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services